Association with poorer outcomes were suggested in studies that found CREBBP mutations in 20% of relapsed/refractory GCB–DLBCL [33], and in a large proportion of relapsed acute lymphoblastic leukemia patients [31, 34]. The gene discussed is CREBBP; the disease is acute lymphoblastic leukemia.